Actuate Therapeutics is set to present the topline results of its Phase 2 trial of elraglusib at the 2025 American Society of Clinical Oncology Annual Meeting. The oral presentation will focus on the combination of elraglusib with gemcitabine/nab-paclitaxel in the first-line treatment of metastatic pancreatic ductal adenocarcinoma.